Moderna Inc. (MRNA)
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna Stock Falls on Vaccine Revenue Concerns
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs.
Moderna's stock is falling. Goldman Sachs says it's no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months.
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Moderna (MRNA) closed at $41.66, marking a +0.6% move from the previous day.
Why Moderna Stock Jumped Over 20% This Week
Shares of Moderna (MRNA -2.31%) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence.
3 Things You Need to Know if You Buy Moderna Today
Based on its share price, down 75% in the last three years, it's easy to write off Moderna (MRNA -2.31%) as a biotech that'll never recover its former glory -- which it built on the success of its coronavirus vaccine program. But where there are widespread bearish sentiments about a stock, there's also often an opportunity for investors who are willing to focus on the long term and appreciate that things won't always be like they are now.
A norovirus vaccine could be on the horizon as cases rise
Moderna is testing a norovirus vaccine in a phase three trial, with results available as soon as this year. Norovirus cases are on the rise this winter, with outbreaks already up more than 30% by December, per data from the Centers for Disease Control and Prevention.
Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines
Moderna stock surged Wednesday after Oracle Chairman Larry Ellison praised the potential of AI in developing medicines. The post Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines appeared first on Investor's Business Daily.
After a Reset Year, Is Moderna Stock Poised for a Comeback?
Biotechnology company Moderna Inc. NASDAQ: MRNA gained the spotlight in the medical sector as a leader in the race toward a COVID-19 vaccine. Its messenger RNA (mRNA) technology garnered acclaim as a next-generation therapy.
3-Stock Lunch: 3M, Moderna, & T-Mobile
Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.
Why Is Moderna Stock Trading Higher On Tuesday?
Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Shares of Moderna (MRNA) took off Tuesday when the biotech firm announced that the U.S. government has awarded it more than a half a billion dollars to develop a vaccine that can be used against bird flu.
